Antibodies to Porphyromonas gingivalis Are Increased in Patients with Severe Periodontitis, and Associate with Presence of Specific Autoantibodies and Myocardial Infarction.
Charlotte de VriesGuillermo RuachoElin KindstedtBarbara Aleksandra PotempaJan PotempaBjörn KlingePernilla LundbergElisabet SvenungssonKarin LundbergPublished in: Journal of clinical medicine (2022)
There is accumulating data suggesting that periodontitis is associated with increased risk of systemic and autoimmune diseases, including cardiovascular disease, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and there is an unmet need to identify these individuals early. With the periodontal bacteria Porphyromonas gingivalis ( Pg ) as one of the key drivers of periodontitis, we set out to investigate whether antibodies to Pg virulence factor arginine gingipain (Rgp) could serve as a biomarker for periodontitis patients at increased risk of autoimmunity and systemic disease. We measured serum anti-Rgp IgG in three study populations: PAROKRANK (779 individuals with myocardial infarction (MI); 719 controls), where 557 had periodontitis, and 312 were positive for autoantibodies associated with RA/SLE; the PerioGene North pilot (41 periodontitis; 39 controls); and an SLE case/control study (101 SLE; 100 controls). Anti-Rgp IgG levels were increased in severe periodontitis compared to controls ( p < 0.0001), in individuals positive for anti-citrullinated protein antibodies ( p = 0.04) and anti-dsDNA antibodies ( p = 0.035), compared to autoantibody-negative individuals; and in MI patients versus matched controls ( p = 0.035). Our data support longitudinal studies addressing the role of anti-Rgp antibodies as biomarkers for periodontitis patients at increased risk of developing autoimmunity linked to RA and SLE, and mechanisms underpinning these associations.
Keyphrases
- systemic lupus erythematosus
- disease activity
- rheumatoid arthritis
- cardiovascular disease
- ankylosing spondylitis
- heart failure
- nitric oxide
- escherichia coli
- pseudomonas aeruginosa
- randomized controlled trial
- metabolic syndrome
- electronic health record
- staphylococcus aureus
- big data
- cystic fibrosis
- drug induced
- newly diagnosed
- early onset
- coronary artery disease
- ejection fraction
- antimicrobial resistance
- biofilm formation
- prognostic factors
- interstitial lung disease
- patient reported
- idiopathic pulmonary fibrosis
- tertiary care